S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
DCTH · Delcath Systems, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Delcath Systems Inc (DCTH)
NASDAQ NMS - GLOBAL MARKET
Health Care
$14.69
-0.06
(-0.41%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$14.69
$14.61
$14.89
52-WEEK RANGE
$14.69
$8.12
$17.42
What's happening
- DCTH is down 0.41% today, trading at $14.69. — Live quote
- Volume today (25,122) is well below its 3-month average of 463,880. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.07 actual vs. $-0.09 estimated (+176.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
DCTH
+46.14%
vs S&P 500
+33.36%
1-YEAR RETURN
DCTH
+29.25%
vs S&P 500
+14.69%
6-MONTH RETURN
DCTH
+36.29%
3-MONTH RETURN
DCTH
+15.22%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.07
Est. $-0.09
BEAT +176.3%
2026-04-26 (Q1 2026)
$-0.03
Est. $-0.09
BEAT +66.1%
2026-01-26 (Q4 2025)
$-0.05
Est. $-0.06
BEAT +20.5%
2025-10-26 (Q3 2025)
$0.02
Est. $0.02
MISS -2.0%
Valuation Measures & Ratios
Enterprise Value4$461.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)5.33
Price / Book73.59
EV4 / Revenue4.83
EV4 / EBITDA513.54
Profit Margin0.56%
Operating Margin-1.90%
Return on Equity (ROE8)0.46%
Return on Assets (ROA9)0.42%
Avg Volume (3M)463,880
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $480.2M | $331.0M | $445.7M | $524.0M | $453.1M |
| P/E | 93.71 | 93.87 | 69.00 | -64.60 | -20.67 |
| Price/Sales | 4.86 | 3.70 | 5.89 | 8.33 | 10.82 |
| Price/Book | 3.96 | 2.94 | 3.88 | 4.99 | 5.65 |
| EV/Revenue | 4.38 | 3.24 | 5.34 | 7.78 | 10.51 |
| ROE | 4.23% | 3.13% | 5.62% | -7.73% | -27.32% |
| ROA | 3.74% | 2.82% | 5.20% | -6.94% | -25.10% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,947,041
Change from Prior Settlement-15.78%
% of Float—
Days to Cover (Short Ratio)5.37
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 20.6% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +29.2%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is 0.6%. Finnhub fundamentals ↗
- Trailing P/E is 956.2, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on DCTH
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.1M | $25.0M | $20.6M | $24.2M | $19.8M | $11.2M | $7.8M | $3.1M |
| Gross profit | $26.1M | $21.3M | $17.9M | $20.8M | $16.9M | $9.6M | $6.2M | $2.2M |
| Operating income | $2.4M | -$1.6M | -$388.0K | $2.6M | $642.0K | -$1.3M | -$3.9M | -$10.3M |
| Net income | $2.7M | -$1.1M | $830.0K | $2.7M | $1.1M | $1.9M | -$13.7M | -$11.1M |
| EPS (diluted) | $0.07 | $-0.03 | $0.02 | $0.07 | $0.03 | $0.06 | $-0.48 | $-0.45 |
| EPS (basic) | $0.07 | $-0.03 | $0.02 | $0.08 | $0.03 | $0.06 | $-0.48 | $-0.45 |
| Operating margin | $8 | -$7 | -$2 | $11 | $3 | -$11 | -$50 | -$327 |
| Net margin | $9 | -$4 | $4 | $11 | $5 | $17 | -$177 | -$354 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $137.0M | $124.8M | $123.6M | $124.3M | $116.9M | $87.3M | $76.6M | $31.7M |
| Total liabilities | $15.9M | $12.1M | $12.4M | $9.4M | $11.9M | $7.1M | $7.8M | $23.1M |
| Stockholders' equity | $121.1M | $112.7M | $111.2M | $114.8M | $105.0M | $80.2M | $68.7M | $8.6M |
| Total current assets | $130.5M | $120.3M | $119.5M | $120.6M | $113.5M | $84.3M | $73.8M | $28.9M |
| Total current liabilities | $13.3M | $10.7M | $10.9M | $8.0M | $10.4M | $5.3M | $6.1M | $21.6M |
| Cash & equivalents | $47.5M | $41.3M | $43.5M | $41.8M | $34.4M | $12.8M | $32.4M | $8.3M |
| Accounts receivable | $15.9M | $14.2M | $11.7M | $13.8M | $15.8M | $13.9M | $10.9M | $6.9M |
| Inventory | $11.7M | $9.8M | $10.3M | $10.7M | $10.5M | $7.1M | $6.9M | $6.6M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $4.0M | $3.7M | $3.2M | $2.7M | $2.4M | $2.0M | $1.8M | $1.7M |
| Accounts payable | $4.0M | $3.5M | $2.7M | $2.1M | $4.7M | $1.6M | $961.0K | $937.0K |
| Accrued liabilities | $9.1M | $7.1M | $8.2M | $5.8M | $5.6M | $3.6M | $5.1M | $5.7M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | $0 | $2.0M |
| Other non-current liabilities | $327.0K | $615.0K | $628.0K | $582.0K | $578.0K | $896.0K | $766.0K | $563.0K |
| Common stock & paid-in capital | $346.0K | $344.0K | $347.0K | $353.0K | $350.0K | $334.0K | $331.0K | $280.0K |
| Retained earnings | -$527.2M | -$529.9M | -$528.8M | -$527.0M | -$527.8M | -$530.5M | -$531.5M | -$528.1M |
| Accumulated other comprehensive income (loss) | $258.0K | $571.0K | $575.0K | $875.0K | $592.0K | $381.0K | $82.0K | $11.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.7M | $857.0K | $8.2M | $4.8M | $7.3M | $2.2M | -$1.0M | -$3.6M |
| Investing cash flow | -$504.0K | -$571.0K | -$561.0K | -$466.0K | -$415.0K | -$25.1M | -$15.2M | -$697.0K |
| Financing cash flow | $962.0K | -$2.4M | -$5.9M | $3.1M | $14.6M | $3.3M | $40.4M | -$2.1M |
| Free cash flow | $5.2M | $287.0K | $7.7M | $4.3M | $6.9M | $2.1M | -$1.2M | -$3.9M |
| Capital expenditures | $503.0K | $570.0K | $550.0K | $459.0K | $398.0K | $140.0K | $229.0K | $216.0K |
| Share-based compensation | — | — | — | — | — | — | — | — |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | $1.8M | $2.4M | -$2.0M | -$2.1M | $1.9M | $3.1M | $4.0M | $3.2M |
| Change in inventory | $1.9M | -$444.0K | -$493.0K | $222.0K | $3.4M | $199.0K | $291.0K | $326.0K |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $32.3M | $15.8M | $31.8M | $10.3M | $21.1M | $30.1M | $20.7M | $11.3M |
| Share repurchases | $11.0K | $3.0M | $6.0M | — | $0 | $0 | $0 | — |
| Debt repaid | — | — | — | — | — | — | $10.6M | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $85.2M | $37.2M | $2.1M | $2.7M | $3.6M |
| Gross profit | $73.4M | $31.0M | $1.4M | $2.0M | $2.9M |
| Operating income | $660.0K | -$12.4M | -$38.2M | -$33.9M | -$24.5M |
| Net income | $2.7M | -$26.4M | -$47.7M | -$36.5M | -$25.6M |
| EPS (diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
| EPS (basic) | $0.08 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
| Operating margin | $1 | -$33 | -$1.8K | -$1.2K | -$690 |
| Net margin | $3 | -$71 | -$2.3K | -$1.3K | -$721 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $123.6M | $76.6M | $38.6M | $17.9M | $33.1M |
| Total liabilities | $12.4M | $7.8M | $22.8M | $23.7M | $21.2M |
| Stockholders' equity | $111.2M | $68.7M | $15.8M | -$5.9M | $12.0M |
| Total current assets | $119.5M | $73.8M | $37.2M | $16.2M | $31.2M |
| Total current liabilities | $10.9M | $6.1M | $16.4M | $14.7M | $6.0M |
| Cash & equivalents | $43.5M | $32.4M | $12.6M | $7.7M | $22.8M |
| Accounts receivable | $11.7M | $10.9M | $241.0K | $366.0K | $44.0K |
| Inventory | $10.3M | $6.9M | $3.3M | $2.0M | $1.4M |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $3.2M | $1.8M | $1.4M | $1.4M | $1.3M |
| Accounts payable | $2.7M | $961.0K | $1.0M | $2.0M | $638.0K |
| Accrued liabilities | $8.2M | $5.1M | $5.2M | $4.7M | $4.1M |
| Deferred revenue (current) | — | — | — | $0 | $170.0K |
| Long-term debt | — | $0 | $10.2M | $15.7M | — |
| Other non-current liabilities | $628.0K | $766.0K | $840.0K | $1.1M | $207.0K |
| Common stock & paid-in capital | $347.0K | $331.0K | $228.0K | $100.0K | $79.0K |
| Retained earnings | -$528.8M | -$531.5M | -$505.2M | -$457.5M | -$421.0M |
| Accumulated other comprehensive income (loss) | $575.0K | $82.0K | $135.0K | -$83.0K | $18.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $22.5M | -$18.7M | -$31.3M | -$24.9M | -$22.6M |
| Investing cash flow | -$26.6M | -$981.0K | -$19.7M | -$209.0K | -$143.0K |
| Financing cash flow | $15.0M | $39.4M | $51.8M | $10.1M | $20.8M |
| Free cash flow | $21.0M | -$19.2M | -$31.3M | -$25.2M | -$22.7M |
| Capital expenditures | $1.5M | $559.0K | $58.0K | $209.0K | $143.0K |
| Deferred income taxes | $0 | $0 | — | — | — |
| Change in accounts receivable | $854.0K | $10.6M | -$125.0K | $322.0K | -$13.0K |
| Change in inventory | $3.3M | $3.6M | $1.3M | $587.0K | $557.0K |
| Change in accounts payable | — | — | — | — | -$1.1M |
| Purchases of investments | $93.2M | $52.5M | $19.7M | $0 | — |
| Share repurchases | $6.0M | $0 | — | — | — |
| Debt repaid | — | $10.6M | $6.3M | $714.0K | — |
| Other financing activities | — | — | — | — | $886.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding DCTH as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-05-05 to 2026-10-13
Recent transactions
- Most recent: Rosalind Advisors, Inc. (Director) — Derivative conversion of 3,627 shares on 2026-10-13.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | Director | Derivative conversion | 2026-10-13 | 3,627 |
| Pennell Sandra | Chief Financial Officer | Open market purchase | 2026-03-06 | 5,533 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | Open market purchase | 2026-03-02 | 11,200 |
| Sylvester John Richard | Reporting person | Open market purchase | 2025-11-21 | 4,386 |
| Vukovic Vojo | CHIEF MEDICAL OFFICER | Option exercise | 2025-06-12 | 42,000 |
| Aharon Gil | Director | In-the-money option exercise | 2025-05-05 | 400,000 |
| SALAMON STEVEN A J | Director | In-the-money option exercise | 2025-05-05 | 400,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-13 | Rosalind Advisors, Inc. | Director | Derivative conversion | 3,627 | $0.00 |
| 2026-10-13 | Rosalind Advisors, Inc. | Director | Other acquisition/disposition | 27,502 | $0.00 |
| 2026-03-06 | Pennell Sandra | Chief Financial Officer | Open market purchase | 5,533 | $9.04 |
| 2026-03-02 | MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | Open market purchase | 11,200 | $8.96 |
| 2025-11-21 | Sylvester John Richard | Reporting person | Open market purchase | 4,386 | $8.89 |
| 2025-11-11 | MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | Open market purchase | 11,500 | $8.53 |
| 2025-06-12 | Vukovic Vojo | CHIEF MEDICAL OFFICER | Option exercise | 42,000 | $4.78 |
| 2025-05-05 | Aharon Gil | Director | In-the-money option exercise | 400,000 | $10.00 |
| 2025-05-05 | SALAMON STEVEN A J | Director | In-the-money option exercise | 400,000 | $10.00 |
| 2025-05-05 | Rosalind Advisors, Inc. | Director | In-the-money option exercise | 400,000 | $10.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:12 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 4 | 2026-10-13 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-13 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-13 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-13 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-13 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-13 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-13 | View on SEC.gov → |
| 2026-05-07 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-07 | 8-K | 2026-05-07 | View on SEC.gov → |
Recent news
Headlines about DCTH (Delcath Systems, Inc.). Links open the publisher — we don’t host full articles.
-
Delcath Systems, Inc. (DCTH) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
DCTH May 2027 30.000 call (DCTH270521C00030000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Yahoo · 2026-10-19 -
Ownership limits block all warrant exercises for Delcath Systems (DCTH) shareholder Rosalind.
Stock Titan · 2026-10-19 -
Delcath Systems Presents Data Regarding Its Clinical Development Programs At European Society For Medical Oncology Congress 2026; Presents Publication Of Analysis Of Percutaneous Hepatic Perfusion With Melphalan Using CH
Benzinga · 2026-10-19 -
DCTH Oct 2026 2.500 call (DCTH261016C00002500) stock price, news, quote and history
Yahoo Finance UK · 2026-10-16 -
How (DCTH) Movements Inform Risk Allocation Models
Stock Traders Daily · 2026-10-15 -
Form 4 Delcath Systems Inc: Rosalind Advisors, Inc. (Director) For: 13 October By Investing.com
Investing.com South Africa · 2026-10-15
No headlines in this category right now — try “All”.